|
BR8108820A
(pt)
|
1980-09-24 |
1982-08-24 |
Cetus Corp |
Processo e sonda de diagnostico
|
|
EP0084796B1
(en)
|
1982-01-22 |
1990-05-02 |
Cetus Corporation |
Hla typing method and cdna probes used therein
|
|
US4582788A
(en)
|
1982-01-22 |
1986-04-15 |
Cetus Corporation |
HLA typing method and cDNA probes used therein
|
|
US4683194A
(en)
|
1984-05-29 |
1987-07-28 |
Cetus Corporation |
Method for detection of polymorphic restriction sites and nucleic acid sequences
|
|
US4595766A
(en)
*
|
1984-10-26 |
1986-06-17 |
Ciba-Geigy Corporation |
Process for the preparation of an indoline carboxylic acid
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
CA1284931C
(en)
|
1986-03-13 |
1991-06-18 |
Henry A. Erlich |
Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
|
|
CA1338457C
(en)
|
1986-08-22 |
1996-07-16 |
Henry A. Erlich |
Purified thermostable enzyme
|
|
US4769461A
(en)
|
1986-09-16 |
1988-09-06 |
American Home Products Corporation |
Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
|
|
WO1994017075A1
(en)
|
1993-01-20 |
1994-08-04 |
A. Menarini Industrie Farmaceutiche Riunite S.R.L. |
Diazepin derivatives and antiviral compositions
|
|
US5519048A
(en)
|
1993-05-27 |
1996-05-21 |
Merrell Pharmaceuticals Inc. |
3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
|
|
WO1994027964A1
(en)
|
1993-05-27 |
1994-12-08 |
Merrell Dow Pharmaceuticals Inc. |
3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists
|
|
US5571813A
(en)
|
1993-06-10 |
1996-11-05 |
Beiersdorf-Lilly Gmbh |
Fused pyrimidine compounds and their use as pharmaceuticals
|
|
JP2000516958A
(ja)
|
1996-08-26 |
2000-12-19 |
ジェネティックス・インスチチュート・インコーポレーテッド |
ホスホリパーゼ酵素の阻害剤
|
|
CN1139572C
(zh)
|
1996-09-30 |
2004-02-25 |
阿温蒂斯药物公司 |
Nmda(n-甲基-d-天冬氨酸)拮抗剂
|
|
US5922752A
(en)
|
1997-06-11 |
1999-07-13 |
Hoechst Marion Roussell, Inc. |
NMDA (n-methyl-d-aspartate) antagonists
|
|
GB9805716D0
(en)
|
1998-03-17 |
1998-05-13 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
WO2002012189A1
(en)
|
2000-08-09 |
2002-02-14 |
Mitsubishi Pharma Corporation |
Fused bicyclic amide compounds and medicinal use thereof
|
|
AU2002312370A1
(en)
|
2001-06-13 |
2002-12-23 |
Roland W. Burli |
Antipathogenic benzamide compounds
|
|
US20040265929A1
(en)
|
2001-11-15 |
2004-12-30 |
The Regents Of The University Of Michigan |
Humoral response to HIP1 in cancer
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
CA2470427C
(en)
|
2001-12-21 |
2012-07-10 |
Cytokinetics, Incorporated |
Compositions and methods for treating heart failure
|
|
MXPA03000966A
(es)
|
2002-02-28 |
2003-09-04 |
Pfizer Prod Inc |
Agentes antidiabeticos.
|
|
GB0205176D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1497278B1
(en)
|
2002-04-11 |
2010-05-26 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic amide derivatives as cytokine inhibitors
|
|
AU2003227360A1
(en)
|
2002-04-25 |
2003-11-10 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel amide derivatives or salts thereof
|
|
US20040142981A1
(en)
|
2002-08-23 |
2004-07-22 |
Atli Thorarensen |
Antibacterial benzoic acid derivatives
|
|
US20040110802A1
(en)
|
2002-08-23 |
2004-06-10 |
Atli Thorarensen |
Antibacterial benzoic acid derivatives
|
|
US7078419B2
(en)
|
2003-03-10 |
2006-07-18 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Cytokine inhibitors
|
|
WO2004096768A1
(en)
|
2003-04-30 |
2004-11-11 |
Pfizer Products Inc. |
Anti-diabetic agents
|
|
US7504401B2
(en)
|
2003-08-29 |
2009-03-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
CA2582327A1
(en)
|
2004-10-01 |
2006-04-13 |
Takao Suzuki |
2-arylcarboxamide-nitrogeneous heterocycle compound
|
|
US7226942B2
(en)
|
2004-11-15 |
2007-06-05 |
Bristol-Myers Squibb Company |
2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
|
|
US7223786B2
(en)
|
2004-11-15 |
2007-05-29 |
Bristol-Myers Squibb Company |
2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
|
|
EP1880994A4
(en)
|
2005-05-11 |
2010-04-14 |
Eisai R&D Man Co Ltd |
INDOLE DERIVED CRYSTAL COMPRISING A PIPERIDINE CYCLE AND PROCESS FOR SYNTHESIZING SAID CRYSTAL
|
|
ES2537898T3
(es)
|
2005-10-25 |
2015-06-15 |
Shionogi & Co., Ltd. |
Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
|
|
US20080280891A1
(en)
|
2006-06-27 |
2008-11-13 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
|
WO2009158375A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Abbott Laboratories |
Aza-cylic indole- 2 -carboxamides and methods of use thereof
|
|
AU2009289649B2
(en)
|
2008-09-03 |
2016-05-05 |
Biomarin Pharmaceutical Inc. |
Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
|
|
WO2011011366A2
(en)
|
2009-07-20 |
2011-01-27 |
Constellation Pharmaceuticals |
Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
|
|
WO2011079102A1
(en)
|
2009-12-23 |
2011-06-30 |
Sanofi |
Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
|
|
EP2528925B1
(en)
|
2010-01-29 |
2017-07-05 |
Hanmi Science Co., Ltd. |
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
|
|
EP2531598A4
(en)
|
2010-02-03 |
2013-05-22 |
Oncotherapy Science Inc |
WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
|
|
JP2012107001A
(ja)
|
2010-10-22 |
2012-06-07 |
Shionogi & Co Ltd |
インドールアミド化合物を含有する医薬
|
|
EP2762472B1
(en)
|
2011-09-28 |
2017-05-24 |
Industry-Academia Cooperation Group of Sejong University |
Selenophene-fused aromatic compound and manufacturing method thereof
|
|
EP2770993A2
(en)
|
2011-10-26 |
2014-09-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method of treating hcv infection with a small molecule chk2 inhibitor
|
|
CA2853501A1
(en)
|
2011-10-27 |
2013-05-02 |
Memorial Sloan-Kettering Cancer Center |
Methyltransferase inhibitors for treating cancer
|
|
US20150289512A1
(en)
|
2012-11-09 |
2015-10-15 |
Sumitomo Chemical Company, Limited |
Method for promoting plant growth
|
|
FR3000492B1
(fr)
|
2012-12-28 |
2015-09-11 |
Oribase Pharma |
Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
|
|
US9446064B2
(en)
|
2013-03-14 |
2016-09-20 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
US9045477B2
(en)
|
2013-03-15 |
2015-06-02 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
SG11201605437YA
(en)
|
2014-01-27 |
2016-08-30 |
Pfizer |
Bifunctional cytotoxic agents
|
|
WO2015143424A2
(en)
|
2014-03-21 |
2015-09-24 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Methods of treating cancer
|
|
WO2015150097A1
(en)
*
|
2014-04-04 |
2015-10-08 |
Iomet Pharma Ltd |
Indole derivatives for use in medicine
|
|
US20170044100A1
(en)
|
2014-04-22 |
2017-02-16 |
The Johns Hopkins University |
Inhibitors of drug-resistant mycobacterium tuberculosis
|
|
WO2016004513A1
(en)
|
2014-07-11 |
2016-01-14 |
Simon Fraser University |
Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
|
|
US9902702B2
(en)
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
US20170232030A1
(en)
|
2014-08-13 |
2017-08-17 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
US10913736B2
(en)
|
2014-08-22 |
2021-02-09 |
University Of Washington |
Specific inhibitors of methionyl-tRNA synthetase
|
|
AU2015315174B2
(en)
*
|
2014-09-10 |
2019-12-12 |
Epizyme, Inc. |
Smyd inhibitors
|
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
WO2017106259A1
(en)
|
2015-12-17 |
2017-06-22 |
Albert Einstein College Of Medicine, Inc. |
Nuclear receptor set domain containing protein 2 transition state and uses thereof
|
|
WO2017156177A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
WO2017156181A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
US10759765B2
(en)
|
2016-04-15 |
2020-09-01 |
Ce Pharm Co., Ltd. |
Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute
|
|
CN106317043B
(zh)
|
2016-08-19 |
2018-11-02 |
成都理工大学 |
一种大麻素受体2激动剂
|
|
EP3535242B1
(en)
|
2016-10-20 |
2024-01-24 |
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
Dna primase and gyrase inhibitors
|
|
EP3592736A1
(en)
|
2017-03-10 |
2020-01-15 |
Rutgers, the State University of New Jersey |
Indole derivatives as efflux pump inhibitors
|
|
CN108976172B
(zh)
|
2017-05-31 |
2021-12-07 |
华东师范大学 |
一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
|
|
US11458121B2
(en)
|
2017-06-26 |
2022-10-04 |
Rutgers, The State University Of New Jersey |
Therapeutic compounds and methods to treat infection
|
|
IL272379B2
(en)
|
2017-08-14 |
2025-11-01 |
Epizyme Inc |
Methods of treating cancer by inhibiting setd2
|
|
WO2019222349A1
(en)
|
2018-05-15 |
2019-11-21 |
Dana-Farber Cancer Institute, Inc. |
Compounds for treating dengue virus infections and other infections
|
|
JP7627209B2
(ja)
*
|
2018-08-14 |
2025-02-05 |
エピザイム，インコーポレイティド |
置換インドール及びその使用方法
|
|
WO2020112872A1
(en)
|
2018-11-30 |
2020-06-04 |
Epizyme, Inc. |
Methods of treating whsc1-overexpressing cancers by inhibiting setd2
|
|
CN121695288A
(zh)
|
2020-02-19 |
2026-03-20 |
Epizyme股份有限公司 |
Setd2抑制剂和相关方法和用途，包括组合疗法
|
|
EP4351552A4
(en)
|
2021-06-09 |
2025-06-18 |
Epizyme, Inc. |
COMBINATION THERAPIES WITH SETD2 INHIBITORS
|
|
AU2022377650A1
(en)
|
2021-11-01 |
2024-05-16 |
Epizyme, Inc. |
Crystalline forms of n-((1r,3s)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1h-indole-2-carboxamide
|